Company intelligence / Profile preview

Pluristyx

Seattle, Washington, United Statespluristyx.com ↗

Ownership: Private
Development stage: Commercial

Overview

No direct clinical results reported. The company enables rapid translation of partner programs from concept through preclinical development toward clinic using its proprietary iPSC lines, gene editing technologies, and manufacturing capabilities. Clients have seen up to a 70% reduction in development timelines.

Therapeutic areas: Other
Modalities: Induced pluripotent stem cell derived therapyGene-edited cell therapyCell therapy
Industry: Contract Manufacturing Organization

Partnerships

Charles River LaboratoriesSinai Health System

Beyond the preview

Go deeper on Pluristyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluristyx.

Explore the full profile